A study of 405,023 UK Biobank participants asked how endocrine, nutritional and metabolic conditions relate to cancer over time. The authors compared a first cancer diagnosis, a further primary cancer and death as separate outcomes. For the protein analysis highlighted in the same paper, 31,866 people contributed to the mediation models. Those numbers belong to different parts of the research.
- The main cohort analysis considered 25 endocrine, nutritional and metabolic conditions. Eight helped define four profiles for further comparisons.
- The protein mediation analysis used 31,866 people. Another analysis, searching for metabolite candidates, used 171,240.
- Associations varied across cancer transitions. The validation dataset came from the UK Biobank cohort.
- Paper date
- 20 November 2026
- Main sample
- 405,023 UK Biobank participants
- Protein mediation analysis
- 31,866 participants
- Design
- Prospective observational cohort
Original publication: 20 Nov 2026 · The date above refers to this brief.
Sample sizes for three analyses in the same paper
people contributing to each analysis
Read each transition from its starting state
Follow participants without a prior diagnosis
The first transition of interest is a first primary cancer.
Start again from the first primary cancer
The model can track a later primary cancer or death from this state.
Read death from the relevant state
Check whether the comparison begins after one or multiple primary cancers.
A new diagnosis and a later outcome have different starting points
The authors used a model that tracks movement between states. A first cancer diagnosis starts with people free of cancer in the model. The analysis of another primary cancer starts with people who already had a first primary cancer. Death can be compared from more than one starting state. The label on each transition tells you who could experience the event being counted.
Source 1 ↗The profiles summarized combinations of conditions
The authors examined 25 conditions and selected eight to build four statistical profiles. Each profile reflected a pattern across multiple diagnoses, with one pattern dominated by type 2 diabetes and another by osteoporosis. The study checked whether the profiles and their associations were reproducible in a held-out dataset from the same biobank.
Source 1 ↗The result can change when the outcome changes
In the validation set, estimated hazard ratios for a first primary cancer ranged from 1.151 to 1.412 across the four profiles compared with the reference group. For death after multiple primary cancers, the profile dominated by lipid and lipoprotein disorders had an estimate of 0.972 (95% CI 0.728 to 1.296). That interval includes 1. A single risk label would conceal the differences between these transitions.
Source 1 ↗The molecular analyses have their own denominators
The protein mediation work used 31,866 people, numerically equivalent to 7.87% of the main cohort count. The metabolite investigation used 171,240 people to look for candidates. A mediation model uses assumptions about how diagnoses, molecules and outcomes are related. Observed data can support a proposed pathway. Establishing a biological mechanism requires additional evidence from other designs.
Source 1 ↗What a useful validation would add
An external cohort could test whether the groups recur with a different mix of people and whether the transition estimates hold with a different health record system. If such profiles are used to make predictions, readers would also need to see how predicted probabilities compare with observed outcomes in new populations.
Source 1 ↗Check the population and outcome behind each estimate
Publisher’s version of record. Checked participant selection, the multistate design, Figure 4 results and the reported protein and metabolite analyses. The underlying data and code were outside this check.
01Does the main cohort size apply to the protein results?
- What was observed
- The main sample included 405,023 people. The protein mediation analysis included 31,866.
- Where the conclusion stops
- The quality and generalizability of the molecular result depend on the subset with the relevant data.
Source 1 · Methods, participant inclusion and Results, protein mediation
02Does a profile have the same association at every stage?
- What was observed
- In the validation set all four profiles were linked to a first primary cancer. The lipid profile estimate for death after multiple primary cancers included 1 in its interval.
- Where the conclusion stops
- A different starting state and outcome change who is compared and what the estimate means.
Source 1 · Results, Figure 4D
Numbers you can inspect
| Measure | Value & unit | Origin & method |
|---|---|---|
| Main cohort | 405023 people | Reported Participants in the main UK Biobank analysis. Source 1 · Methods, participant inclusion and exclusion |
| Conditions studied | 25 conditions | Reported Endocrine, nutritional and metabolic conditions examined. Source 1 · Abstract and Results |
| Conditions used for profile definition | 8 conditions | Reported Selected indicators for the four profiles. Source 1 · Results, profile definition |
| Statistical profiles | 4 profiles | Reported Diagnosis profiles C1 through C4. Source 1 · Results, Figure 4 |
| Protein mediation sample | 31866 people | Reported Participants in the protein mediation analysis. Source 1 · Results, Figure 6D–E |
| Protein mediation count divided by main sample count | 7.87 percent | Calculated 31,866 divided by 405,023, times 100, rounded to two decimals. Source 1 · Methods and Results, protein mediation |
| Metabolite candidate sample | 171240 people | Reported Participants in the metabolite analysis described in Results. Source 1 · Results, identification of metabolic mediators |
| Smallest first cancer hazard ratio in validation set | 1.151 hazard ratio | Reported Lower end of the reported range across four profile estimates. Source 1 · Results, Figure 4D |
| Largest first cancer hazard ratio in validation set | 1.412 hazard ratio | Reported Upper end of the reported range across four profile estimates. Source 1 · Results, Figure 4D |
| Lipid profile, death after multiple primary cancers | 0.972 hazard ratio | Reported Validation estimate. 95% CI 0.728 to 1.296. Source 1 · Results, Figure 4D |
Compare the actual experiments
These studies answer different questions. Read the unit and endpoint before comparing results.
| Study | Unit & setting | Readout | Interpretation boundary |
|---|---|---|---|
| Counting a cohort and its molecular subsets Source 1 · Methods and Results, protein mediation | Participants with different measurement sets | Disease outcomes and molecular assays | Biomarker analyses have their own denominators even in large biobanks. |
| Reading time-to-event comparisons Source 1 · Results, Figure 4D | Biobank participants and participants in a review of imaging age studies | Transition-specific hazards and all-cause mortality hazards | Each hazard ratio belongs to an outcome and a defined starting group. |
The export includes claims, available numbers, methods and source locations. It contains our reading notes and published summaries; it is not raw participant data or an independent reanalysis.
Evidence update · 21 Nov 2026
First publication. Any calculations in this brief use reported figures. The reading notes identify possible follow-up questions. AI source check; no human editorial or clinical review.
Which participants underpin each result?
| Analysis | Participants | Question addressed |
|---|---|---|
| Cancer transitions | 405,023 | Track recorded diagnoses and deaths across follow-up. |
| Protein mediation | 31,866 | Evaluate protein candidates in statistical mediation models. |
| Metabolite candidate analysis | 171,240 | Look for metabolite patterns linked to the profiles. |
Counts come from participant selection and from the protein mediation and metabolite candidate sections.
Your questions, answered
Was protein mediation tested in all 405,023 people?
The main cohort covered 405,023 people. The protein mediation analysis used 31,866 participants.
What does a transition measure?
It describes a change from one defined state to another, such as moving from no recorded cancer to a first primary diagnosis.
Did a new profile mean the same association at every transition?
The estimates differed across outcomes. For one profile, the estimate for death after multiple cancers had a confidence interval that included a hazard ratio of 1.
What does the validation set establish?
It tests whether analyses built in one subset give consistent results in another subset of the biobank. An independent cohort would test the results in a different setting.
Limits of this interpretation
- The main data come from an observational UK Biobank sample. Held-out participants come from the same underlying cohort.
- The molecular analyses depend on who had the relevant measurements and on model assumptions.
- Hazard ratios compare modeled rates for specific transitions. An absolute probability would need follow-up timing and a starting risk.
Sources & transparency
- Wu, Yao, Chu et al. (2026) — Endocrine, nutritional and metabolic diseases drive cancer risk through subtype-specific and shared proteomic mediators
Publisher’s version of record. Checked participant selection, the multistate design, Figure 4 results and the reported protein and metabolite analyses. The underlying data and code were outside this check. · Accessed 21 Nov 2026
DOI: 10.1038/s41467-026-78791-4
Prepared and source-checked with AI for Press-news Team. The source notes identify the material available during preparation. The article received no human editorial or clinical review. The source list supports the reported results and the calculations shown.
Source check: AI source check — primary research and stated source limits
Clinical review: Not applicable to this educational guide
Suggest a correction